Peptide LibraryVentfort
Also known as: Vessel bioregulator
Ventfort (also called Vessel bioregulator) is a khavinson vascular bioregulator. Ventfort is a peptide preparation derived from vascular tissue and marketed in the Khavinson tradition for cardiovascular support.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- Not established in humans
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Endothelium (proposed)
Vendor price snapshot
None of these listings has a price per mg to compare. From public vendor listings; confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 1
- Listed offers
- 2
- Price per mg
- —
Research summary
Peptide preparation derived from vascular tissue and sold as a cardiovascular bioregulator in the Khavinson tradition. It is a mixture of low-molecular-weight peptides rather than a single characterised compound, and is distinct from Vesugen, the synthetic tripeptide associated with the same tissue. No study of Ventfort itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators, and it is not FDA-approved.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Ventfort profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Ventfort dosage: no established human dose
Ventfort has no established human dosage. It is sold as capsules described as a blood-vessel peptide bioregulator, a tissue-derived peptide complex rather than a single defined peptide. No trial of it is registered on ClinicalTrials.gov, and no study of Ventfort itself is indexed in PubMed. The nearest human evidence is for vesugen, a different synthetic vascular peptide, and that abstract gives no dose.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: Ventfort is marketed as a peptide complex from vascular tissue, sold as an oral capsule. No human, animal or cell study of this product is indexed in PubMed. The related human report is for vesugen (Lys-Glu-Asp), a synthetic tripeptide, and it states no dose. Nothing here establishes a human dose, route or interval for Ventfort.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Related vascular peptide (analog) — vesugen in vasculogenic erectile dysfunction (2014)Clinical trial · Clinical report on a different compound (analog evidence), Russian-language publicationStudied an analog, not Ventfort itself | Patients with vasculogenic erectile dysfunction linked to atherosclerosis (n=41) | Not stated in the indexed abstract | Not stated in the indexed abstract | — | — | Better blood flow in the main penile arteries after vesugen alone, by clinical and instrument measures | [The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people]. Adv Gerontol. 2014. |
Where sources disagree
- Daily capsule protocols for Ventfort are published by sellers. No registered trial or indexed study reports a dose for it.
- Ventfort (a tissue-derived complex) and vesugen (a synthetic tripeptide) are different products. The vesugen profile covers vesugen itself.
Sequence & molecular data
| Amino acid sequence | Peptide complex A-3 (mixture; sequence not defined) |
|---|---|
| Half-life | Not established in humans |
| Appearance | White lyophilized powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Ventfort is a peptide preparation derived from vascular tissue and marketed in the Khavinson tradition for cardiovascular support. It is a complex of low-molecular-weight peptides rather than a single defined compound, so no specific sequence, receptor or downstream pathway can be identified, and it is distinct from Vesugen, the synthetic tripeptide associated with the same tissue. The proposed mechanism is the series hypothesis that tissue-derived peptides influence transcription in the corresponding tissue, with claimed effects on endothelial protein synthesis. Evidence is historical, regional and uncontrolled.
Origin
Peptide preparation from vascular tissue (per its description).
Targets
Studies
- Peptides and Ageing (class-level)
- Tissue-specific effects of peptides (class-level)
- Peptide bioregulation of aging: results and prospects (class-level evidence)
- Mechanisms underlying geroprotective effects of peptides (class-level evidence)
- Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b (class-level evidence)
Regulatory & research status
Ventfort is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
Ventfort side effects
Ventfort has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Not characterized
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Ventfort: frequently asked questions
What is Ventfort?
Peptide preparation derived from vascular tissue and sold as a cardiovascular bioregulator in the Khavinson tradition. It is a mixture of low-molecular-weight peptides rather than a single characterised compound, and is distinct from Vesugen, the synthetic tripeptide associated with the same tissue. No study of Ventfort itself is indexed in PubMed; the studies cited here are class-level work on short peptide bioregulators, and it is not FDA-approved.
How does Ventfort work?
Ventfort is a peptide preparation derived from vascular tissue and marketed in the Khavinson tradition for cardiovascular support. It is a complex of low-molecular-weight peptides rather than a single defined compound, so no specific sequence, receptor or downstream pathway can be identified, and it is distinct from Vesugen, the synthetic tripeptide associated with the same tissue.
Is Ventfort FDA approved?
No. Ventfort is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Ventfort?
Reported half-life for Ventfort is Not established in humans. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of Ventfort?
Ventfort has the sequence Peptide complex A-3 (mixture; sequence not defined), giving a chain of 2 amino acids. Its molecular formula is C15H23N3O10.
What peptides are similar to Ventfort?
Compounds most often compared with Ventfort include Bonomarlot, Bronchogen, Cardiogen and Cartalax. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Class-level evidence — Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett, 2002External reference
- Class-level evidence — Tissue-specific effects of peptides. Bull Exp Biol Med, 2001External reference
- Class-level evidence — Peptide bioregulation of aging: results and prospects — Biogerontology, 2010External reference
- Class-level evidence — Mechanisms underlying geroprotective effects of peptides — Bull Exp Biol Med, 2002External reference
- Class-level evidence — Epigenetic mechanisms of peptide-driven regulation and neuroprotective protein FKBP1b — Mol Biol (Mosk), 2019External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 4
This Ventfort profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Ventfort research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →